Targeted near-infrared (NIR) optical imaging can be used in vivo to detect specific tissues, including malignant cells. A series of NIR fluorescent
ligands targeting the prostate-specific membrane
antigen (PSMA) was synthesized and each compound was tested for its ability to image PSMA+ tissues in experimental models of
prostate cancer. The agents were prepared by conjugating commercially available active
esters of NIR
dyes, including IRDye800CW, IRDye800RS,
Cy5.5, Cy7, or a derivative of
indocyanine green (ICG) to the terminal
amine group of (S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic
acid 1, (14S,18S)-1-amino-8,16-dioxo-3,6-dioxa-9,15,17-triazaicosane-14,18,20-tricarboxylic
acid 2 and (3S,7S)-26-amino-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic
acid 3. The K(i) values for the
dye-inhibitor conjugates ranged from 1 to 700 pM. All compounds proved capable of imaging PSMA+
tumors selectively to varying degrees depending on the choice of fluorophore and linker. The highest
tumor uptake was observed with IRDye800CW employing a poly(
ethylene glycol) or
lysine-suberate linker, as in 800CW-2 and 800CW-3, while the highest
tumor to nontarget tissue ratios were obtained for Cy7 with these same linkers, as in Cy7-2 and Cy7-3. Compounds 2 and 3 provide useful scaffolds for targeting of PSMA+ tissues in vivo and should be useful for preparing NIR
dye conjugates designed specifically for clinical intraoperative optical imaging devices.